VIENNA — The highly selective oral Janus kinase (JAK) inhibitor SHR0302 (ivarmacitinib) enables more patients with active rheumatoid arthritis to meet American College of Rheumatology (ACR) response ...
Lynk Pharmaceuticals has posted positive topline results from a Phase III trial on its next generation Janus kinase 1 (JAK1) inhibitor, zemprocitinib, in rheumatoid arthritis (RA). During the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results